Literature DB >> 25560844

NAFLD in 2014: Genetics, diagnostics and therapeutic advances in NAFLD.

Mary E Rinella1, Arun J Sanyal2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25560844      PMCID： PMC4984668          DOI： 10.1038/nrgastro.2014.232

Source DB:  PubMed          Journal:  Nat Rev Gastroenterol Hepatol        ISSN： 1759-5045            Impact factor:   46.802


× No keyword cloud information.
  10 in total

1.  Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease.

Authors:  Brent A Neuschwander-Tetri; Jeanne M Clark; Nathan M Bass; Mark L Van Natta; Aynur Unalp-Arida; James Tonascia; Claudia O Zein; Elizabeth M Brunt; David E Kleiner; Arthur J McCullough; Arun J Sanyal; Anna Mae Diehl; Joel E Lavine; Naga Chalasani; Kris V Kowdley
Journal:  Hepatology       Date:  2010-09       Impact factor: 17.425

Review 2.  The global NAFLD epidemic.

Authors:  Rohit Loomba; Arun J Sanyal
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2013-09-17       Impact factor: 46.802

3.  Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial.

Authors:  Brent A Neuschwander-Tetri; Rohit Loomba; Arun J Sanyal; Joel E Lavine; Mark L Van Natta; Manal F Abdelmalek; Naga Chalasani; Srinivasan Dasarathy; Anna Mae Diehl; Bilal Hameed; Kris V Kowdley; Arthur McCullough; Norah Terrault; Jeanne M Clark; James Tonascia; Elizabeth M Brunt; David E Kleiner; Edward Doo
Journal:  Lancet       Date:  2014-11-07       Impact factor: 79.321

4.  Noninvasive differentiation of simple steatosis and steatohepatitis by using gadoxetic acid-enhanced MR imaging in patients with nonalcoholic fatty liver disease: a proof-of-concept study.

Authors:  Nina Bastati; Diana Feier; Andreas Wibmer; Stefan Traussnigg; Csilla Balassy; Dietmar Tamandl; Henrik Einspieler; Friedrich Wrba; Michael Trauner; Christian Herold; Ahmed Ba-Ssalamah
Journal:  Radiology       Date:  2014-02-27       Impact factor: 11.105

5.  Relations of lipoprotein subclass levels and low-density lipoprotein size to progression of coronary artery disease in the Pravastatin Limitation of Atherosclerosis in the Coronary Arteries (PLAC-I) trial.

Authors:  Robert S Rosenson; James D Otvos; David S Freedman
Journal:  Am J Cardiol       Date:  2002-07-15       Impact factor: 2.778

6.  Severity of nonalcoholic fatty liver disease and progression to cirrhosis are associated with atherogenic lipoprotein profile.

Authors:  Mohammad S Siddiqui; Michael Fuchs; Michael O Idowu; Velimir A Luketic; Sherry Boyett; Carol Sargeant; Richard T Stravitz; Puneet Puri; Scott Matherly; Richard K Sterling; Melissa Contos; Arun J Sanyal
Journal:  Clin Gastroenterol Hepatol       Date:  2014-10-13       Impact factor: 11.382

7.  Suspected nonalcoholic fatty liver disease and mortality risk in a population-based cohort study.

Authors:  Winston Dunn; Ronghui Xu; Deborah L Wingard; Christopher Rogers; Paul Angulo; Zobair M Younossi; Jeffrey B Schwimmer
Journal:  Am J Gastroenterol       Date:  2008-08-05       Impact factor: 10.864

Review 8.  Epidemiology of hepatocellular carcinoma: consider the population.

Authors:  Sahil Mittal; Hashem B El-Serag
Journal:  J Clin Gastroenterol       Date:  2013-07       Impact factor: 3.062

9.  Nonalcoholic steatohepatitis is the most rapidly growing indication for liver transplantation in patients with hepatocellular carcinoma in the U.S.

Authors:  Robert J Wong; Ramsey Cheung; Aijaz Ahmed
Journal:  Hepatology       Date:  2014-04-25       Impact factor: 17.425

10.  Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease.

Authors:  Julia Kozlitina; Eriks Smagris; Stefan Stender; Børge G Nordestgaard; Heather H Zhou; Anne Tybjærg-Hansen; Thomas F Vogt; Helen H Hobbs; Jonathan C Cohen
Journal:  Nat Genet       Date:  2014-02-16       Impact factor: 38.330
  10 in total
  21 in total

1.  PNPLA3 I148M variant affects non-alcoholic fatty liver disease in liver transplant recipients.

Authors:  Zheng-Tao Liu; Tian-Chi Chen; Xiao-Xiao Lu; Jun Cheng; Hai-Yang Xie; Lin Zhou; Shu-Sen Zheng
Journal:  World J Gastroenterol       Date:  2015-09-14       Impact factor: 5.742

2.  Hepatocyte mitochondrial DNA drives nonalcoholic steatohepatitis by activation of TLR9.

Authors:  Irma Garcia-Martinez; Nicola Santoro; Yonglin Chen; Rafaz Hoque; Xinshou Ouyang; Sonia Caprio; Mark J Shlomchik; Robert Lee Coffman; Albert Candia; Wajahat Zafar Mehal
Journal:  J Clin Invest       Date:  2016-01-25       Impact factor: 14.808

Review 3.  The role of the gut microbiota in NAFLD.

Authors:  Christopher Leung; Leni Rivera; John B Furness; Peter W Angus
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-06-08       Impact factor: 46.802

Review 4.  Lipotoxic lethal and sublethal stress signaling in hepatocytes: relevance to NASH pathogenesis.

Authors:  Petra Hirsova; Samar H Ibrahim; Gregory J Gores; Harmeet Malhi
Journal:  J Lipid Res       Date:  2016-04-05       Impact factor: 5.922

5.  c-Jun N-terminal kinase-mediated Rubicon expression enhances hepatocyte lipoapoptosis and promotes hepatocyte ballooning.

Authors:  Akiko Suzuki; Keisuke Kakisaka; Yuji Suzuki; Ting Wang; Yasuhiro Takikawa
Journal:  World J Gastroenterol       Date:  2016-07-28       Impact factor: 5.374

Review 6.  Drosophila tools and assays for the study of human diseases.

Authors:  Berrak Ugur; Kuchuan Chen; Hugo J Bellen
Journal:  Dis Model Mech       Date:  2016-03       Impact factor: 5.758

Review 7.  NKT cell subsets as key participants in liver physiology and pathology.

Authors:  Keya Bandyopadhyay; Idania Marrero; Vipin Kumar
Journal:  Cell Mol Immunol       Date:  2016-03-14       Impact factor: 11.530

Review 8.  Current Management of NAFLD.

Authors:  Mihai Alexandru Munteanu; Georgiana Anca Nagy; Petru Adrian Mircea
Journal:  Clujul Med       Date:  2016-01-15

Review 9.  Micronutrient Antioxidants and Nonalcoholic Fatty Liver Disease.

Authors:  Guanliang Chen; Yinhua Ni; Naoto Nagata; Liang Xu; Tsuguhito Ota
Journal:  Int J Mol Sci       Date:  2016-08-23       Impact factor: 5.923

10.  SPARC expression is associated with hepatic injury in rodents and humans with non-alcoholic fatty liver disease.

Authors:  Guillermo Mazzolini; Catalina Atorrasagasti; Agostina Onorato; Estanislao Peixoto; Martin Schlattjan; Jan-Peter Sowa; Svenja Sydor; Guido Gerken; Ali Canbay
Journal:  Sci Rep       Date:  2018-01-15       Impact factor: 4.379
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.